Main Variants of Disease Progression
Although various types of these neoplasms share very similar clinical and morphological features, two main clinical variants are classically distinguished depending on the lineage of the tumor cells.
- Pre-B-lymphoblastic tumors
This type typically presents classically as leukemia. The bone marrow is involved in the pathological process, showing massive replacement by tumor elements. As a result, immature blast cells inevitably enter the systemic circulation and are readily detected in peripheral blood tests.
- Pre-T-lymphoblastic tumors
This variant is characterized by its primary localization. Since normal T-lymphocyte differentiation occurs in the thymus, it frequently serves as the primary site of tumor origin. The disease typically manifests as a mass lesion—a large tumor infiltrate in the mediastinum. Subsequently, the pathological process does not remain localized and rapidly transforms into a systemic leukemia with involvement of the bone marrow and other organs.
Clinical Manifestations and Hematopoietic Failure
An important feature of acute lymphoblastic leukemias is that the clinical picture is practically independent of cytogenesis (i.e., whether the tumor developed from B- or T-precursors). The disease always has a prominent acute onset.
All core symptoms are directly caused by severe failure of normal hematopoiesis. Proliferating lymphoblasts crowd out normal hematopoietic lineages, leading to the following consequences:
- Anemia (decreased red blood cell count and hemoglobin);
- Bleeding (due to suppression of the megakaryocytic lineage and thrombocytopenia);
- Recurrent infections (due to a lack of mature, functionally competent leukocytes).
Additionally, tumor cells are capable of migration, leading to specific leukemic infiltration of various internal organs. One of the most characteristic and debilitating symptoms for the patient is severe bone pain, which occurs precisely because of dense infiltration of the bone marrow space by actively dividing tumor cells.
Central Nervous System Involvement (Neuroleukemia)
Specific involvement of the CNS, or neuroleukemia, can occur in any form of leukemia, but it is most characteristic of the lymphoblastic variant and represents a major clinical challenge.
Pathogenesis of Neuroleukemia: Tumor cells penetrate the structures of the central nervous system and actively accumulate in the subarachnoid space, causing dense infiltration of the leptomeninges.
Treatment Challenges and Consequences: The main difficulty lies in the presence of the blood-brain barrier. Standard administration of cytotoxic drugs fails to achieve effective therapeutic concentrations in the cerebrospinal fluid (CSF). The exception is ultra-high doses of methotrexate. Consequently, lymphoblasts that have entered the CNS successfully evade the destructive effects of standard chemotherapy. As a result, the central nervous system becomes a pharmacological "sanctuary" for the tumor, acting as a potential reservoir and source from which disease relapse is highly likely to develop later.
Basics of Diagnostics
Establishing an accurate diagnosis when acute lymphoblastic leukemia is suspected allows no delay due to the extremely rapid progression of the pathology. The diagnostic workup is based on three main pillars:
- Thorough evaluation of clinical symptoms (identifying signs of acute onset, anemia, hemorrhagic syndrome, infections, and bone pain).
- Analysis of the peripheral blood smear (searching for blast cells and signs of suppressed normal hematopoietic lineages).
- Examination of bone marrow aspirate (the key method that visualizes massive lymphoblastic infiltration and definitively confirms the diagnosis).